Latest Peplin news



news 

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

21-Dec-09

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

12-Nov-09

Letter to our CDI Holders read more


Privacy policy

Peplin Limited ("Peplin") is committed to protecting the personal information it collects and is bound by the National Privacy Principles.

The information that Peplin collects about you depends on your interaction with us. If you are a shareholder or supporter of Peplin for example, we may collect details such as name, address, phone/fax numbers and email address, primarily for the purpose of providing you with relevant information about Peplin and its activities.

Generally, we will only collect personal information directly from you, and use this information only for the purpose of providing you with information and advice relating to matters of relevance to you.

We do not sell, rent or disclose your personal information to any third parties without your consent.

Peplin takes all reasonable measures to ensure that your personal information is stored or secured safely.

If you wish to know the personal information we hold about you, please submit a request for access in writing to the contact details below. If complying with your request requires considerable time and expense on our part, we may charge you a reasonable fee for providing you with copies of the information.

If you require access, or have any other concerns about the way Peplin handles your personal information, please contact us at the address set out below:

The Privacy Officer

Peplin Limited
PO Box 3325
NEWSTEAD LPO   QLD  4006

Email: privacy@peplin.com
Tel: +61 7 3250 1200